Evaluation of Diagnostic Yield of EUS-Guided Tissue Sampling
Evaluation of Diagnostic Yield of EUS-Guided Tissue Sampling
All patients will receive standard medical care and no experimental interventions will be
 performed. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a
 well-established procedure commonly used for the investigation of lesions within or adjacent
 to the gastrointestinal (GI) lumen (i.e. pancreas, liver, mediastinal masses, left adrenal
 gland, lymph nodes, and subepithelial lesions). EUS-guided tissue sampling has been commonly
 performed with different size and types of aspiration and core biopsy needles.
Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a well-established procedure
 commonly used for the investigation of lesions within or adjacent to the gastrointestinal
 (GI) lumen (i.e. pancreas, liver, mediastinal masses, left adrenal gland, lymph nodes, and
 subepithelial lesions). EUS-guided tissue sampling has been commonly performed with different
 size and types of aspiration and core biopsy needles. More recently, a novel
 through-the-needle microforceps has been introduced. The MorayTM microforceps fits through a
 19-gauge FNA needle and allows targeted tissue sampling under EUS visualization.

 Aim - To prospectively evaluate the safety and diagnostic yield of the through-the-needle
 microforceps for pancreatic and non-pancreatic solid, cystic and mixed solid/cystic lesions.
Inclusion Criteria:

 1. Age >18 years old

 2. Patients referred for EUS-guided tissue sampling for lesions (i.e. pancreas, liver,
 mediastinal masses, left adrenal gland, lymph nodes, and subepithelial lesions).

 3. Target lesion should be ≥ 15 mm in size (long axis).

 Exclusion Criteria:

 1. Any contraindication to performing endoscopy

 2. Unable to provide informed consent